LDC exits Prism Medical UK
18 Dec 2018
Our partnership with LDC provided the financial firepower and strategic guidance we needed to kick-start an acquisitive growth strategy and the team’s support has been instrumental in helping us to achieve our ambitions."
They have helped to guide a growth journey that has ultimately seen us expand across the UK, ramp up exports and enter new market segments – all of which means we can bring more of our market leading products to those who need it the most.”
“The past four years have been a period of true transformation and we now have an even stronger platform on which to build as we enter the next stage of our journey with Limerston Capital.”
The sale was led by Investment Director Matt Newbold and Head of South West and Wales Andy Lyndon.
Matt Newbold, Investment Director at LDC in Birmingham, added: “Over the past four years Stuart and his team have built a truly formidable business – one underpinned by the quality of its product, service and proposition. While quality is vital for any business operating in the care sector, this unwavering focus, combined with astute management, has helped Prism to deliver strong and sustainable growth. It’s been a pleasure to support Stuart and his team and we wish them every success on the next phase of their growth journey.”
Prism Medial UK and the shareholders were advised by Clearwater International and Gateley PLC, with EY Parthenon, KPMG and JLT Speciality providing due diligence support. Management were advised by Cattaneo Corporate Finance and Freeths.